IXICO PLC — M&A Activity 2022

Jul 26, 2022

National Storage Mechanism | Additional information

RNS Number : 7780T

IXICO plc

26 July 2022

IXICO plc

("IXICO" or the "Company")

This announcement replaces RNS number 2135T released on 21 July 2022 at 07.00.

Contract win for a Phase 2 Huntington's disease trial worth circa £2.1m

IXICO plc (AIM: IXI), the precision analytics company delivering intelligent insights in neuroscience, announces that it has been selected by a leading global pharma company to support their drug development programme in Huntington's disease ('HD'). HD is a rare, inherited disease that causes the progressive breakdown of nerve cells in the brain affecting movement, mood and thinking abilities, leading to irreversible decline and eventual death.

Across previous HD trials, IXICO has deployed radiology services and advanced MRI techniques to enable patient eligibility and safety monitoring and to improve understanding of the pharmacodynamic aspects of the treatment. This understanding is now supporting the design, planning and implementation of further clinical research.

Having built an extensive portfolio of proprietary imaging data management and analysis technologies for investigation of neurological disorders since its inception in 2004, IXICO continues to develop its extensive portfolio of advanced neuroimaging solutions and services across the entire drug development lifecycle, from Phase I through to commercialisation.

Giulio Cerroni, CEO of IXICO, commented: "We are delighted to continue our partnership with one of the world's leading pharmaceutical companies working in the field of neurodegenerative diseases."

For further information please contact:

IXICO plc	+44 (0)20 3763 7499
Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser and sole broker)		+44 (0)20 7397 8900
Giles Balleny / Max Gould (Corporate Finance)
Michael F Johnson / Tamar Cranford-Smith (Sales)

About IXICO

IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's, Parkinson's, Alzheimer's disease and Multiple Sclerosis. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.  

IXICO has developed and deployed breakthrough machine learning AI data analytics, at scale, through its remote access TrialTracker technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.

More information is available on www.IXICO.com and follow us on Twitter @IXICOnews

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

CNTBQLFLLDLLBBB